Developing technologies for personalized medicine may be misused to popularize the idea that one can infer a person’s genetic makeup from observer-defined or self-reported assignment to a race or ethnic group.
Some commentators say comparative trials of FDA-approved drugs are overburdened by current Common Rule regulations and that researchers should not be required to obtain explicit consent for participation in the most innocuous of these trials.
Anne Drapkin Lyerly, MD, MA and Ruth R. Faden, PhD, MPH
Participation in a research study—in which there are rigorous standards and close monitoring—may be a safer context for the use of medications in pregnancy than the clinical setting, where the evidence base is lacking.
How can clinicians respond to the alarmingly high rates of maternal mortality in the U.S., and address racial disparities between black and white mothers? This month on Ethics Talk, we discuss how clinicians can improve maternal outcomes.
Medical education must acknowledge the problematic use of race as a biological or epidemiological risk factor in research and the controversy over race.
AMA J Ethics. 2017;19(6):518-527. doi:
10.1001/journalofethics.2017.19.6.peer1-1706.
The FDA’s expanded access pathway allows patients with no other therapeutic options to request access to investigational agents, but manufacturers do not often grant it.
AMA J Ethics. 2015;17(12):1142-1146. doi:
10.1001/journalofethics.2015.17.12.stas1-1512.
The American Medical Association Code of Medical Ethics’ opinions on professionalism and the use of social media, sexual misconduct in the practice of medicine, sexual or romantic relations between physicians and key third parties, and physicians’ duty to care for the poor.
AMA J Ethics. 2015;17(5):432-434. doi:
10.1001/journalofethics.2015.17.5.coet1-1505.